Vertex Pharmaceuticals Inc. (VRTX) announced after the bell Tuesday that results from two Phase 3 studies of the tezacaftor (VX-661) / ivacaftor combination treatment that showed statistically significant improvements in lung function in patients with cystic fibrosis.
from RTT - Before the Bell http://ift.tt/2oed2ym
via IFTTT
No comments:
Post a Comment